Renub Research forecasts the China IVF market to reach about US$9.04 billion through 2030. IVF includes fertilizing a woman’s egg with a person’s sperm in a lab, boosting thought charges for people with fertility problems. Lifestyle adjustments like behind-schedule pregnancies and urbanization contribute to China’s declining fertility price. Government initiatives improving compensation policies for IVF remedies bolster adoption. Ongoing innovation and technological improvements in IVF techniques, devices, and merchandise are expected to pressure the market boom.
In 2023, the China In-Vitro Fertilization (IVF) Market reached US$ 5.37 billion. It is projected to develop at a CAGR of 7.72% from 2024 to 2030. Factors using the worldwide IVF market encompass growing male infertility, an increase within the median age of first-time moms, weight problems, declining fertility prices, and alcohol intake. Increased awareness of infertility and superior treatment options fuels the demand for IVF. Women prioritizing education, careers, and late marriages power the rising median age of first-time moms. Delayed pregnancies, specifically after age 35, contribute to being pregnant, headaches, and infertility, in addition to boosting the IVF marketplace. Additionally, declining fertility rates internationally prompt governments to promote IVF to reduce growth costs. China has 539 IVF facilities, with plans to set up more to meet emerging demand.
The burgeoning popularity of medical tourism and the growing range of presidential tasks are predicted to strengthen the growth of this place in the coming years. Economic development has spurred first-rate expansion within the Chinese in-vitro fertilization (IVF) market. Increased prosperity has brought on lifestyle changes, which include behind-schedule childbearing and heightened infertility prices because of age-related factors. Consequently, there has been a surge in demand for fertility remedies, including IVF. Furthermore, more suitable healthcare infrastructure and heightened cognizance about infertility remedies have made IVF more readily available. With a burgeoning middle class and governmental help for reproductive health services, the continuing financial prosperity in China continues to pressure the expansion of the IVF market.
Donor eggs are anticipated to be one of the sought-after treatments in the China In-Vitro Fertilization (IVF) market.
Donor eggs are increasingly preferred for IVF in China due to advancements in reproductive medicine, higher awareness about infertility options, and changing societal attitudes. Couples grappling with fertility challenges find donor eggs a viable solution for successful pregnancies, given their promising success rates. The availability of donor egg banks and specialized fertility clinics further boosts their adoption. Overall, the rising acceptance of donor eggs represents a significant shift in China’s fertility treatment landscape, providing hope for individuals and couples aspiring to parenthood.
Disposable devices are forecasted to be extensively utilized instruments in the China In-Vitro Fertilization (IVF) market.
Disposable devices are increasingly prevalent in China’s IVF market, serving essential roles in various procedures. These single-use instruments offer convenience, sterility, and cost-effectiveness, which are crucial in maintaining hygiene and minimizing contamination risks inherent in IVF procedures. Their adoption underscores advancements in medical technology and a growing emphasis on patient safety and comfort. As demand for IVF treatments rises in China, disposable devices are expected to remain pivotal, enhancing procedure efficiency and reliability while upholding high standards of patient care.
ICSI IVF is expected to be extensively employed in the China In-Vitro Fertilization (IVF) market.
ICSI IVF is set to become a primary technique in China’s IVF market, involving direct sperm injection into eggs for fertilization and embryonic development. Its rising prominence is attributed to high success rates in addressing male infertility and enhancing pregnancy chances. It also aids couples in dealing with sperm-related challenges, expanding its adoption in infertility treatments. Widely available and effective, ICSI IVF is favored by clinics and practitioners nationwide. As demand for assisted reproductive technologies grows, ICSI IVF is expected to persist as a top choice for conception, pivotal in fulfilling couples’ reproductive goals in China.
Fertility clinics are expected to witness a significant surge in usage within the China In-Vitro Fertilization (IVF) market.
The China IVF market is poised for a notable uptick in the utilization of fertility clinics. As demand for assisted reproductive technologies escalates, fueled by factors such as changing lifestyles and rising infertility rates, fertility clinics are becoming increasingly essential. These clinics offer specialized services and expertise in IVF treatments, catering to the diverse needs of individuals and couples seeking fertility assistance. Additionally, advancements in medical technology and the availability of comprehensive reproductive healthcare services further drive the reliance on fertility clinics. With their pivotal role in providing personalized and effective fertility treatments, fertility clinics are expected to experience a significant surge in demand within the Chinese IVF market.
Key Player
Key companies in the China in-vitro fertilization (IVF) market include Vitrolife, Cloudnine, Nova IVI Fertility, Monash IVF, Maria Fertility Hospital, Bangkok Fertility Center, and EMD Serono, Inc.
Â
Treatment Types – China In-Vitro Fertilization (IVF) Market breakup in 4 viewpoints:
- Fresh Embryo
- Frozen Embryo
- Donor Egg
- Others
Â
Instrument – China In-Vitro Fertilization (IVF) Market breakup in 3 viewpoints:
- Culture Media
- Disposable Devices
- Capital Equipment
Â
Procedure – China In-Vitro Fertilization (IVF) Market breakup in 3 viewpoints:
- ICSI IVF
- Non-ICSI IVF
- IUI Canada
Â
End-User – China In-Vitro Fertilization (IVF) Market breakup in 3 viewpoints:
- Fertility Clinics
- Hospitals
- Others
All the Key players have been covered from 3 Viewpoints:
- Overview
- Recent Development
- Revenue Analysis
Â
Company Analysis:
- Vitrolife
- Cloudnine
- Nova IVI Fertility
- Monash IVF
- Maria Fertility Hospital
- Bangkok Fertility Center
- EMD Serono, Inc.